Siglec-9 defines and restrains a natural killer subpopulation highly cytotoxic to HIV-infected cells
暂无分享,去创建一个
D. Weiner | M. Betts | C. Shikuma | Qin Liu | L. Ndhlovu | Ziyang Xu | N. Roan | M. Abdel-Mohsen | C. Tomescu | Han Xiao | G. Chew | Opeyemi S Adeniji | A. George | L. Kuri-Cervantes | K. Muthumani | Chenfei Yu | Michelle Ho | Costin Tomescu
[1] Z. Ball,et al. Precision Modification of Native Antibodies. , 2021, Bioconjugate chemistry.
[2] Zeru Tian,et al. Synthesis of precision antibody conjugates using proximity-induced chemistry , 2021, Theranostics.
[3] F. Kirchhoff,et al. SIV-induced terminally differentiated adaptive NK cells in lymph nodes associated with enhanced MHC-E restricted activity , 2021, Nature Communications.
[4] M. Betts,et al. Phenotypic Characterization of SLex+ and CLA+ CD4+ T Cells , 2020, STAR protocols.
[5] C. Bertozzi,et al. Targeted glycan degradation potentiates the anticancer immune response in vivo , 2020, Nature Chemical Biology.
[6] B. Liao,et al. Systemic HIV and SIV latency reversal via non-canonical NF-κB signalling in vivo , 2020, Nature.
[7] J. Kim,et al. Synthetic nucleic acid antibody prophylaxis confers rapid and durable protective immunity against Zika virus challenge , 2019, Human vaccines & immunotherapeutics.
[8] Daniel W. Kulp,et al. In vivo delivery of synthetic DNA-encoded antibodies induces broad HIV-1-neutralizing activity. , 2019, The Journal of clinical investigation.
[9] A. Varki,et al. Sialic acid–binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses , 2019, Cellular and Molecular Life Sciences.
[10] M. O'Dwyer,et al. Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer , 2019, Front. Immunol..
[11] P. Romero,et al. Siglec-9 Regulates an Effector Memory CD8+ T-cell Subset That Congregates in the Melanoma Tumor Microenvironment , 2019, Cancer Immunology Research.
[12] G. Nolan,et al. Identification of NK Cell Subpopulations That Differentiate HIV-Infected Subject Cohorts with Diverse Levels of Virus Control , 2019, Journal of Virology.
[13] Juan Tang,et al. Proximity-Induced Site-Specific Antibody Conjugation. , 2018, Bioconjugate chemistry.
[14] C. Amos,et al. Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells , 2018, The Journal of clinical investigation.
[15] Lifen Gao,et al. Decreased Siglec-9 Expression on Natural Killer Cell Subset Associated With Persistent HBV Replication , 2018, Front. Immunol..
[16] Z. ZuluMichael,et al. Reduced Expression of Siglec-7, NKG2A, and CD57 on Terminally Differentiated CD56−CD16+ Natural Killer Cell Subset Is Associated with Natural Killer Cell Dysfunction in Chronic HIV-1 Clade C Infection , 2017 .
[17] B. Jacquelin,et al. Natural killer cells migrate into and control simian immunodeficiency virus replication in lymph node follicles in African green monkeys , 2017, Nature Medicine.
[18] J. Lifson,et al. Defining total-body AIDS-virus burden with implications for curative strategies , 2017, Nature Medicine.
[19] M. Rossetti,et al. A Flow Cytometry-Based Cytotoxicity Assay for the Assessment of Human NK Cell Activity. , 2017, Journal of visualized experiments : JoVE.
[20] L. Montaner,et al. HCV viraemia associates with NK cell activation and dysfunction in antiretroviral therapy‐treated HIV/HCV‐co‐infected subjects , 2017, Journal of viral hepatitis.
[21] A. Varki,et al. Siglec-7 restores β-cell function and survival and reduces inflammation in pancreatic islets from patients with diabetes , 2017, Scientific Reports.
[22] L. Montaner,et al. IFN-α augments NK-mediated antibody-dependent cellular cytotoxicity (ADCC) of HIV-1 infected autologous CD4+ T cells regardless of MHC-I downregulation. , 2017, AIDS.
[23] Carolyn R Bertozzi,et al. Precision glycocalyx editing as a strategy for cancer immunotherapy , 2016, Proceedings of the National Academy of Sciences.
[24] R. Siliciano,et al. Defective proviruses rapidly accumulate during acute HIV-1 infection , 2016, Nature Medicine.
[25] T. D. de Gruijl,et al. Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer , 2016, PloS one.
[26] Nico Pfeifer,et al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1 , 2016, Science.
[27] G. Alter,et al. NK Cells in HIV Disease , 2016, Current HIV/AIDS Reports.
[28] Rebecca Hoh,et al. Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. , 2015, The lancet. HIV.
[29] G. Pantaleo,et al. The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo , 2015, PLoS pathogens.
[30] M. Carrington,et al. Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat , 2015, Journal of Virology.
[31] C. Heyser,et al. Siglec receptors impact mammalian lifespan by modulating oxidative stress , 2015, eLife.
[32] D. Hazuda,et al. Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy , 2014, PLoS pathogens.
[33] D. Hazuda,et al. HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat. , 2014, The Journal of infectious diseases.
[34] S. Ávila-Ríos,et al. Activation of NK cells is associated with HIV‐1 disease progression , 2014, Journal of Leukocyte Biology.
[35] P. Romero,et al. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. , 2014, The Journal of clinical investigation.
[36] R. Siliciano,et al. A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[37] R. Maserati,et al. Sialic acid-binding Ig-like lectin-7 interacts with HIV-1 gp120 and facilitates infection of CD4pos T cells and macrophages , 2013, Retrovirology.
[38] Stephen M. Canham,et al. Glycocalyx Engineering Reveals a Siglec-Based Mechanism for NK Cell Immunoevasion , 2013, Nature chemical biology.
[39] Sarah B. Laskey,et al. Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure , 2013, Cell.
[40] D. Havlir,et al. The distribution of HIV DNA and RNA in cell subsets differs in gut and blood of HIV-positive patients on ART: implications for viral persistence. , 2013, The Journal of infectious diseases.
[41] S. Boni,et al. Natural killer cells in HIV controller patients express an activated effector phenotype and do not up-regulate NKp44 on IL-2 stimulation , 2013, Proceedings of the National Academy of Sciences.
[42] R. Siliciano,et al. HIV-1 eradication strategies: design and assessment , 2013, Current opinion in HIV and AIDS.
[43] Brigitte Autran,et al. Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study , 2013, PLoS pathogens.
[44] J. Eron,et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy , 2012, Nature.
[45] A. Varki,et al. Multifarious roles of sialic acids in immunity , 2012, Annals of the New York Academy of Sciences.
[46] M. Caligiuri,et al. Innate or Adaptive Immunity? The Example of Natural Killer Cells , 2011, Science.
[47] C. Rancourt,et al. Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes , 2010, Molecular Cancer.
[48] D. Nixon,et al. Functionally distinct subsets of human NK cells and monocyte/DC-like cells identified by coexpression of CD56, CD7, and CD4. , 2009, Blood.
[49] A. Moretta,et al. The decreased expression of Siglec-7 represents an early marker of dysfunctional natural killer-cell subsets associated with high levels of HIV-1 viremia. , 2009, Blood.
[50] L. Montaner,et al. NK Cell Lysis of HIV-1-Infected Autologous CD4 Primary T Cells: Requirement for IFN-Mediated NK Activation by Plasmacytoid Dendritic Cells1 , 2007, The Journal of Immunology.
[51] Ajit Varki,et al. Siglecs and their roles in the immune system , 2007, Nature Reviews Immunology.
[52] D. Venzon,et al. A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. , 2006, Journal of immunological methods.
[53] A. Fauci,et al. Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[54] F. Lopez,et al. The Membrane-Proximal Immunoreceptor Tyrosine-Based Inhibitory Motif Is Critical for the Inhibitory Signaling Mediated by Siglecs-7 and -9, CD33-Related Siglecs Expressed on Human Monocytes and NK Cells1 , 2004, The Journal of Immunology.
[55] James C Paulson,et al. Negative Regulation of T Cell Receptor Signaling by Siglec-7 (p70/AIRM) and Siglec-9* , 2004, Journal of Biological Chemistry.
[56] Adelheid Cerwenka,et al. Natural killer cells, viruses and cancer , 2001, Nature Reviews Immunology.
[57] P. Crocker,et al. Siglec-9, a Novel Sialic Acid Binding Member of the Immunoglobulin Superfamily Expressed Broadly on Human Blood Leukocytes* , 2000, The Journal of Biological Chemistry.
[58] M A Nowak,et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[59] D. Richman,et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.
[60] R Brookmeyer,et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.
[61] R. Siliciano,et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection , 1997, Nature.
[62] Robert F. Siliciano,et al. In vivo fate of HIV-1-infected T cells: Quantitative analysis of the transition to stable latency , 1995, Nature Medicine.
[63] L. Montaner,et al. IFN-α augments natural killer-mediated antibody-dependent cellular cytotoxicity of HIV-1-infected autologous CD4+ T cells regardless of major histocompatibility complex class 1 downregulation. , 2017, AIDS.
[64] Mahendra Kumar,et al. Human immunodeficiency virus type 1 RNA Levels in different regions of human brain: Quantification using real-time reverse transcriptase-polymerase chain reaction , 2011, Journal of NeuroVirology.
[65] Lewis L Lanier,et al. NK cell recognition. , 2005, Annual review of immunology.
[66] Lewis L Lanier,et al. Natural killer cells and cancer. , 2003, Advances in cancer research.